Ketotifen therapy in chronic graft-versus-host disease (cGVHD): Effect on mast cells and fibroblasts

Keyphrases

• Fibroblasts 100%
• Mast Cells 100%
• Graft-versus-host Disease (GvHD) 100%
• Disease Effects 100%
• Ketotifen 100%
• Supernatant 40%
• Peripheral Blood Mononuclear Cells 40%
• Histamine Release 30%
• Prostaglandin E2 20%
• 3T3 Fibroblasts 20%
• Fibroblast Proliferation 20%
• Skin Biopsy 20%
• Treatment Options 10%
• Cell number 10%
• Cell Count 10%
• Murine Model 10%
• Clinical Improvement 10%
• Current Treatment 10%
• Activation State 10%
• In Vitro Effect 10%
• Mast Cell Stabilizing 10%
• Toluidine Blue Staining 10%
• Therapeutic Role 10%
• Cell Activation 10%
• Anti-H 10%
• Bacterial Sepsis 10%
• H1-antihistamines 10%

Immunology and Microbiology

• Mast Cell 100%
• Chronic Graft Versus Host Disease 100%
• Ketotifen 100%
• Fibroblast 100%
• Peripheral Blood Mononuclear Cell 40%
• Histamine Release 30%
• Supernatant 20%
• Prostaglandin E2 20%
• Cell Count 10%
• Cell Activation 10%
• Normal Value 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Chronic Graft Versus Host Disease 100%
• Ketotifen 100%
• Histamine 30%
• Prostaglandin E2 20%
• Disease 10%
• Side Effect 10%
• Antihistaminic Agent 10%
• Tolonium Chloride 10%
• Sepsis 10%